This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these template messages)(Learn how and when to remove this template message)
|Traded as||NASDAQ: GNVC|
|Headquarters||Gaithersburg, Maryland, U.S.|
|Douglas J. Swirsky, President and CEO|
|Products||CGF166Clinical trial#Phase 1/2|
Number of employees
GenVec, Inc. (NASDAQ: GNVC) is a biopharmaceutical company working to build a pipeline of therapeutics and vaccines based on its adenovector technology platform that can realize the promise of gene-based medicine. The company's lead product candidate for hearing loss and balance disorders, partnered with Novartis, is in a first-in-man gene delivery Phase 1/2 clinical trial in patients with severe to profound hearing loss. GenVec therapeutics and vaccines have been administered to over 3,000 clinical study subjects.
|This article about a medical, pharmaceutical or biotechnological corporation or company is a stub. You can help Wikipedia by expanding it.|